Table 4.
Investigator’s Assessment of Hemostatic Efficacy per Treated NSB Events and Overall Prophylactic Efficacy
| Bleeding Type | Hemostatic Efficacy Assessment of Treated NSB Events | |||||||
|---|---|---|---|---|---|---|---|---|
| On-Demand (N=12) | Prophylaxis (N=4) | |||||||
| Number (%) of NSB Events | Number (%) of NSB Events | |||||||
| n | Excellent | Good | Moderate | n | Excellent | Good | Moderate | |
| All bleedings | 80 | 36 (45.0) | 44 (55.0) | – | 73 | 59 (80.8) | 14 (19.2) | – |
| Spontaneous | 62 | 26 (41.9) | 36 (58.1) | – | 59 | 49 (83.1) | 10 (16.9) | – |
| Trauma | 18 | 10 (55.6) | 8 (44.4) | – | 14 | 10 (71.4) | 4 (28.6) | – |
| Post-surgery | 0 | – | – | – | 0 | – | – | – |
| Major | 26 | 13 (50.0) | 13 (50.0) | – | 3 | 1 (33.3) | 2 (66.7) | – |
| Minor | 54 | 23 (42.6) | 31 (57.4) | – | 70 | 58 (82.9) | 12 (17.1) | – |
| Joint | 11 | 2 (18.2) | 9 (81.8) | – | 3 | – | 3 (100) | – |
| Mucosal | 65 | 30 (46.2) | 35 (53.8) | – | 62 | 53 (85.5) | 9 (14.5) | – |
| Muscle | 1 | 1 (100) | – | – | 0 | – | – | – |
| Other | 3 | 3 (100) | – | – | 8 | 6 (75.0) | 2 (25.0) | – |
| Visit | Overall Hemostatic Efficacy Assessment of Prophylaxis | |||||||
| Number (%) of Patients | ||||||||
| – | – | – | – | N | Excellent | Good | Moderate | |
| Month 3 | – | – | – | – | 4 | 2 (50.0) | 2 (50.0) | – |
| Month 6 | – | – | – | – | 4 | 4 (100) | – | – |
| Month 9 | – | – | – | – | 4 | 4 (100) | – | – |
| Month 12 | – | – | – | – | 4 | 3 (75.0) | 1 (25.0) | – |
Note: Bleedings with missing investigator’s assessment for efficacy and those for which no treatment was needed are not included.
Abbreviations: N, total number of patients; n, number of treated bleeding events; NSB, non-surgical bleeding.